Paratek Pharmaceuticals Inc
F:N4CN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Paratek Pharmaceuticals Inc
Gross Profit
Paratek Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Paratek Pharmaceuticals Inc
F:N4CN
|
Gross Profit
$151.7m
|
CAGR 3-Years
86%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$65.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$35B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$47.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$53B
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$54.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
23%
|
CAGR 10-Years
14%
|
|
Paratek Pharmaceuticals Inc
Glance View
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 207 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The firm's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.
See Also
What is Paratek Pharmaceuticals Inc's Gross Profit?
Gross Profit
151.7m
USD
Based on the financial report for Jun 30, 2023, Paratek Pharmaceuticals Inc's Gross Profit amounts to 151.7m USD.
What is Paratek Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 3Y
86%
Over the last year, the Gross Profit growth was 62%. The average annual Gross Profit growth rates for Paratek Pharmaceuticals Inc have been 86% over the past three years .
